Indaptus Therapeutics (INDP) expands Patent Portfolio in China, Japan, and Israel

Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments.

Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, “The allowance of these patents in key international markets highlights the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of people affected by HBV and HIV worldwide, expanding our intellectual property reinforces the novelty and therapeutic promise of our approach.”

A Growing Global Health Need

Chronic HBV infections remain a major health concern, especially in Asia.

• China has approximately 87 million people living with chronic HBV, nearly one-third of all cases worldwide.
• Japan has approximately 1.1 – 1.2 million people affected by chronic HBV.
• In 2022, HBV caused an estimated 1.1 million deaths worldwide, primarily due to cirrhosis and liver cancer.

Despite available treatments, new therapies are urgently needed to improve long-term outcomes.

A Unique Approach to Infectious Disease and Cancer Treatment

Preclinical studies demonstrated that Indaptus’ Decoy bacteria—which are attenuated and killed bacteria designed to stimulate the immune system—produced significant single-agent activity in standard models of chronic HBV and HIV infections.

Patented candidates from Indaptus’ Decoy platform have also produced single agent activity and durable, combination-mediated tumor eradication in multiple pre-clinical cancer models and one candidate (Decoy20) is currently being evaluated in a Phase 1 clinical trial in the U.S. for patients with advanced cancers.

With these new patents, Indaptus continues to strengthen its position as a leader in immunotherapy innovation, advancing treatments for both infectious diseases and cancer.

You May Also Be Interested In

• Fed’s Waller open to September rate hold - if disinflation holds up
• CN sets monthly record moving 2.50 MMT of grain in August
• Globant launches MuleSoft AI Pod for enterprise API integration